Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.49 |
| ▸ | PPARA | Q07869 | 9/20 | 0.49 |
| ▸ | PPARG | P37231 | 6/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201341 | 0.91 | PPARD (0.59) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL6314006 | 0.91 | PPARD (0.58) | PPARDPPARAPPARGPTPN1 | |
| Lithium SCHEMBL6314015 | 0.91 | PPARD (0.58) | PPARDPPARAPPARGPTPN1 | |
| SCHEMBL6315442 | 0.89 | PPARD (0.48) | PPARDPPARAPPARGMRGPRX4RXRA | |
| SCHEMBL5512600 | 0.74 | PPARD (0.76) | PPARDPPARAPPARG | |
| SCHEMBL5511919 | 0.73 | PPARD (0.63) | PPARDPPARAPPARG | |
| SCHEMBL6344074 | 0.71 | PPARD (0.64) | PPARDPPARAPPARG | |
| SCHEMBL14364308 | 0.66 | PPARD (0.45) | PPARDMRGPRX4PTPN1 | |
| SCHEMBL2869606 | 0.66 | PPARD (1.00) | PPARDPPARAPPARG | |
| SCHEMBL8405629 | 0.66 | MAOB (0.47) | PPARDMRGPRX4PTPN1PTPN2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964983-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | AUERBACH BRUCE J (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | AUERBACH BRUCE J (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885PPARG 3/4885 |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.